Ingalls & Snyder LLC raised its position in Zoetis Inc. (NYSE:ZTS – Free Report) by 1.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,299 shares of the company’s stock after purchasing an additional 194 shares during the quarter. Ingalls & Snyder LLC’s holdings in Zoetis were worth $2,598,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently made changes to their positions in the business. Simplify Asset Management Inc. bought a new stake in Zoetis during the 3rd quarter valued at $11,684,000. Bank Pictet & Cie Asia Ltd. raised its stake in shares of Zoetis by 41.0% during the second quarter. Bank Pictet & Cie Asia Ltd. now owns 37,500 shares of the company’s stock valued at $6,501,000 after purchasing an additional 10,900 shares in the last quarter. Swedbank AB lifted its holdings in Zoetis by 56.2% in the second quarter. Swedbank AB now owns 1,946,277 shares of the company’s stock worth $337,407,000 after purchasing an additional 700,398 shares during the period. B&L Asset Management LLC bought a new position in Zoetis in the 3rd quarter valued at about $563,000. Finally, Raymond James & Associates raised its position in shares of Zoetis by 6.1% during the 2nd quarter. Raymond James & Associates now owns 794,419 shares of the company’s stock worth $137,720,000 after buying an additional 45,597 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.
Analyst Ratings Changes
Several research analysts have recently issued reports on ZTS shares. BTIG Research increased their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. JPMorgan Chase & Co. lifted their price target on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a report on Monday. Piper Sandler raised their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Finally, Leerink Partners assumed coverage on shares of Zoetis in a research report on Monday. They issued an “outperform” rating and a $215.00 price target on the stock. Eleven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $220.80.
Zoetis Trading Up 0.5 %
ZTS stock traded up $0.88 during mid-day trading on Tuesday, reaching $177.69. 226,699 shares of the stock traded hands, compared to its average volume of 2,534,772. The stock’s fifty day moving average is $183.83 and its 200-day moving average is $180.97. The company has a market cap of $80.17 billion, a P/E ratio of 33.24, a P/E/G ratio of 2.69 and a beta of 0.89. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92.
Zoetis (NYSE:ZTS – Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the prior year, the firm earned $1.36 EPS. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. As a group, sell-side analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current year.
Zoetis Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 0.97%. The ex-dividend date is Thursday, October 31st. Zoetis’s payout ratio is 32.52%.
Zoetis Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Articles
- Five stocks we like better than Zoetis
- EV Stocks and How to Profit from Them
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
- Stock Market Sectors: What Are They and How Many Are There?Â
- 3 S&P 500 Stocks With Sky High Risk-Adjusted Returns
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Trending Stocks: How to Spot, Trade, and Profit Safely
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.